Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)
Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –
Biogen total assets
Total assets on the balance sheet at the end of each period.
Biogen's total assets was $32.05B at Sep 30, 2026. For fiscal 2025 it was $29.44B, up 5.0% from the year before. Over ten years it grew 4.2% a year on average. The highest annual figure on record is $29.44B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.44B | +5.0% |
| FY2024 | Dec 31, 2024 | $28.05B | +4.5% |
| FY2023 | Dec 31, 2023 | $26.84B | +9.3% |
| FY2022 | Dec 31, 2022 | $24.55B | +2.8% |
| FY2021 | Dec 31, 2021 | $23.88B | -3.0% |
| FY2020 | Dec 31, 2020 | $24.62B | -9.6% |
| FY2019 | Dec 31, 2019 | $27.23B | +7.7% |
| FY2018 | Dec 31, 2018 | $25.29B | +6.9% |
| FY2017 | Dec 31, 2017 | $23.65B | +3.4% |
| FY2016 | Dec 31, 2016 | $22.88B | +17.3% |
| FY2015 | Dec 31, 2015 | $19.50B | +36.3% |
| FY2014 | Dec 31, 2014 | $14.31B | +20.7% |
| FY2013 | Dec 31, 2013 | $11.86B | +17.1% |
| FY2012 | Dec 31, 2012 | $10.13B | +11.9% |
| FY2011 | Dec 31, 2011 | $9.05B | +11.8% |
| FY2010 | Dec 31, 2010 | $8.09B | -5.4% |
| FY2009 | Dec 31, 2009 | $8.55B | +0.9% |
| FY2008 | Dec 31, 2008 | $8.48B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $32.05B | +9.7% |
| Q2 FY2026 | Jun 30, 2026 | $32.09B | +13.3% |
| Q1 FY2026 | Mar 31, 2026 | $29.48B | +5.2% |
| Q4 FY2025 | Dec 31, 2025 | $29.44B | +5.0% |
| Q3 FY2025 | Sep 30, 2025 | $29.21B | +3.2% |
| Q2 FY2025 | Jun 30, 2025 | $28.33B | +5.7% |
| Q1 FY2025 | Mar 31, 2025 | $28.03B | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | $28.05B | +4.5% |
| Q3 FY2024 | Sep 30, 2024 | $28.31B | +0.4% |
| Q2 FY2024 | Jun 30, 2024 | $26.80B | +6.5% |
| Q1 FY2024 | Mar 31, 2024 | $26.57B | +8.0% |
| Q4 FY2023 | Dec 31, 2023 | $26.84B | +9.3% |
| Q3 FY2023 | Sep 30, 2023 | $28.19B | +13.4% |
| Q2 FY2023 | Jun 30, 2023 | $25.16B | +0.3% |
| Q1 FY2023 | Mar 31, 2023 | $24.60B | +4.2% |
| Q4 FY2022 | Dec 31, 2022 | $24.55B | +2.8% |
| Q3 FY2022 | Sep 30, 2022 | $24.85B | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $25.08B | +2.5% |
| Q1 FY2022 | Mar 31, 2022 | $23.61B | -1.0% |
| Q4 FY2021 | Dec 31, 2021 | $23.88B | -3.0% |
| Q3 FY2021 | Sep 30, 2021 | $23.81B | -4.5% |
| Q2 FY2021 | Jun 30, 2021 | $24.47B | -4.1% |
| Q1 FY2021 | Mar 31, 2021 | $23.85B | -8.7% |
| Q4 FY2020 | Dec 31, 2020 | $24.62B | -9.6% |
| Q3 FY2020 | Sep 30, 2020 | $24.93B | -9.3% |
| Q2 FY2020 | Jun 30, 2020 | $25.51B | -3.0% |
| Q1 FY2020 | Mar 31, 2020 | $26.12B | -1.2% |
| Q4 FY2019 | Dec 31, 2019 | $27.23B | +7.7% |
| Q3 FY2019 | Sep 30, 2019 | $27.48B | +7.8% |
| Q2 FY2019 | Jun 30, 2019 | $26.29B | +9.7% |
| Q1 FY2019 | Mar 31, 2019 | $26.45B | +1.4% |
| Q4 FY2018 | Dec 31, 2018 | $25.29B | +6.9% |
| Q3 FY2018 | Sep 30, 2018 | $25.49B | +10.5% |
| Q2 FY2018 | Jun 30, 2018 | $23.95B | +10.1% |
| Q1 FY2018 | Mar 31, 2018 | $26.09B | +23.1% |
| Q4 FY2017 | Dec 31, 2017 | $23.65B | +3.4% |
| Q3 FY2017 | Sep 30, 2017 | $23.07B | – |
| Q2 FY2017 | Jun 30, 2017 | $21.76B | – |
| Q1 FY2017 | Mar 31, 2017 | $21.20B | – |
| Q4 FY2016 | Dec 31, 2016 | $22.88B | – |
See a number that looks wrong?